



High-risk human papillomavirus cervical infections among healthy women in Guadeloupe[☆]



Nadège Cordel^{a,*}, Camille Ragin^b, Monique Trival^c, Benoît Tressières^d, Eustase Janky^e

^a Dermatology and Internal Medicine Unit, Guadeloupe University Hospital and EA 4546, CELTEC, Antilles University, BP 465, 97159 Pointe-à-Pitre cedex, Guadeloupe

^b Cancer Prevention and Control Program, Fox Chase Cancer Center, Temple Health and Department of Epidemiology and Biostatistics, Temple University, College of Public Health, Philadelphia, Pennsylvania, USA

^c Pathology Laboratory Trival Monique, Jarry, Guadeloupe

^d Centre d'Investigation Clinique Antilles-Guyane, Guadeloupe, Inserm CIC 1424

^e Parent–Child Department, Gynecology and Obstetrics Unit, Guadeloupe University Hospital, EA 4546, CELTEC, Antilles University, Guadeloupe

ARTICLE INFO

Article history:

Received 5 May 2015

Received in revised form 12 October 2015

Accepted 16 October 2015

Corresponding Editor: Eskild Petersen, Aarhus, Denmark.

Keywords:

High-risk human papillomavirus
Cervical infection
Cytology
Prevalence
Caribbean

SUMMARY

Objective: To assess high-risk human papillomavirus (HR HPV) cervical infections and their type distribution among healthy women in Guadeloupe, French West Indies.

Methods: The details of consecutive non-pregnant women who attended cervical cancer screening and had HPV genotyping performed at the largest pathology laboratory on the island from January 1, 2013 to December 31, 2014 were recorded retrospectively. All women with available HPV genotyping results were included in the study.

Results: HR HPV genotyping results for 618 women (median age 42 years) were collected. The overall prevalence rate of HR HPV cervical infection was 36.1% (95% confidence interval (CI) 32.3–40.0%), with the following type distribution: HPV 16 or 18 irrespective of other HPV types, 7.3% (95% CI 5.4–9.6%); other HR HPV types excluding HPV 16 or 18, 28.8% (95% CI 25.3–32.5%). The prevalence rates of overall HR HPV and HR HPV other than 16 or 18 infection increased significantly ($p < 0.001$) with the severity of cytology grade, from 19.7% for normal cytology to 53.8% in atypical squamous cells of undetermined significance (ASC-US) and 67.7% in low-grade squamous intraepithelial lesions (LSIL).

Conclusion: The high prevalence rate of HR HPV cervical infection with genotypes other than 16 and 18 in Guadeloupe, irrespective of age and the cytology grade, suggests a potential benefit of the new nine-valent HPV vaccine to prevent HPV infection-related cancers in this Caribbean country.

© 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Virus-related cancers are a leading cause of death in Caribbean countries,^{1,2} and have been identified as an important public health problem by the French West Indies cancer registries. The most common of these viruses associated with cancer are the human papillomavirus (HPV) types designated as ‘high risk’ (HR); these are implicated in 99% of cervical cancer, in 40–80% of anogenital cancers other than cervical, and in approximately 25% of head and neck cancers.^{3–9} The most prevalent HR HPV types in

invasive cervical cancers worldwide are types 16 and 18, which are the primary targets of current HPV vaccination programs.^{10–12}

Although the prevalence of HPV infection and incidence rates of cervical cancer are high in the Caribbean, limited data are available on the prevalence of HR HPV cervical infections among healthy Caribbean women.^{1,2,10,13–17} In addition, very few studies have been performed to describe the HR HPV type distribution in this population. Investigators of the African Caribbean Cancer Consortium have reported a high prevalence rate of HPV 45 rather than HPV 16 or 18 in Tobago, Jamaica, and Barbados.^{14–16} No data are available for the French West Indies. The recent US Food and Drug Administration (FDA) approval of a second-generation HPV vaccine that targets five HR HPV types (i.e., 31, 33, 45, 52, and 58) in addition to 16 and 18 warrants the evaluation of HR HPV cervical infections in the whole Caribbean.¹⁸ This new prophylactic

[☆] Nadège Cordel and Camille Ragin are members of the African Caribbean Cancer Consortium.

* Corresponding author. Tel.: +33 590 590 891 566; fax: +33 590 590 891 615. E-mail address: nadege.cordel@chu-guadeloupe.fr (N. Cordel).

vaccine may be more appropriate in Caribbean vaccination programs for the prevention of cervical cancer.^{10,19}

Guadeloupe, an overseas department of France, is the largest island of the French West Indies (405 000 inhabitants, mostly Black Caribbean persons of African and European descent). A retrospective study was conducted on the island of Guadeloupe in order to assess the prevalence of cervical HR HPV infections and the type distribution of HR HPV among healthy women in this Caribbean country.

2. Patients and methods

2.1. Data and sample collection

The details of consecutive non-pregnant women who attended cervical cancer screening and had HPV genotyping performed at the largest pathology laboratory on the island from January 1, 2013 to December 31, 2014 were recorded. All cases with available HPV genotyping results of liquid-based cytology samples were included in the study.

Pathology charts were reviewed retrospectively using the computerized database of the laboratory and DIAMIC software. The following data were recorded: resident status to confirm permanent residence on the island of Guadeloupe during the study period, date of birth, date of sampling, and cytology results according to the Bethesda System 2001.²⁰ Samples were classified as atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL).

2.2. HPV testing and genotyping

The genotyping analysis of liquid-based cytology specimens collected in PreservCyt (Hologic Corp.) was performed independently from the histopathological examination, using a semi-genotyping kit (Cobas 4800 HPV test, Roche Diagnostics). This qualitative multiplex assay provides specific genotyping of HPV 16 and 18 while concurrently detecting the other HR HPV types (i.e., 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) in a pooled analysis using amplification of the target DNA by PCR and nucleic acid hybridization.

2.3. Statistical analysis

Results were recorded as numbers and frequencies. The prevalence rates of HPV infection were calculated with 95% confidence intervals (CIs). Age was described using the median and interquartile range (Q1–Q3). Stratification according to age was performed to analyze the HR HPV type distribution by cytology grade within each age group: 18–24, 25–29, 30–39, 40–49, 50–64, and ≥65 years. Cross-tabulations were analyzed by Chi-square test or Fisher's exact test when appropriate. Comparisons of prevalence rates with other countries were based on the Chi-square test.

For all analyses, two-sided *p*-values of less than 0.05 were considered statistically significant. Data management and the statistical analysis were performed using SPSS v.17.0 software (SPSS Inc., Chicago, IL, USA).

2.4. Ethical considerations

This retrospective study was approved by the Ethics Committee for Non-interventional Research of Rouen University Hospital (registered number E2015-37).

3. Results

A total of 618 consecutive HR HPV genotyping results from 618 women were collected. The median age of the study population was 42 years (Q1–Q3 32–52 years). The overall prevalence rate of HR HPV cervical infection was 36.1% (95% CI 32.3–40.0%). The distribution of HR HPV types was as follows: HPV 16 or 18 irrespective of other HPV types, 7.3% (95% CI 5.4–9.6%); other HR HPV types excluding HPV 16 and 18, 28.8% (95% CI 25.3–32.5%).

Cytology results were available for 592 of the 618 cases and were classified as normal for 447 women, ASC-US for 106 women, LSIL for 31 women, and HSIL for eight women.

Interestingly, the overall prevalence rate of HR HPV cervical infection increased significantly ($p < 0.001$) with the severity of cytology grade from normal to LSIL, as did the prevalence rate of HR HPV other than 16 or 18 infection. These varied from 25.1% (95% CI 21.1–29.3%) and 19.7% (95% CI 16.1–23.7%) for normal cytology to 65.1% (95% CI 55.2–74.1%) and 53.8% (95% CI 43.8–63.5%) in ASC-US and 77.4% (95% CI 58.9–90.4%) and 67.7% (95% CI 48.6–83.3%) in LSIL (Table 1). The HSIL group was not considered for the analysis because of its small size ($n = 8$).

Table 2 shows the HR HPV type distribution by country (i.e., Guadeloupe, France, developed regions, and Tobago) for normal cytology; data were obtained from Heard et al.,²¹ the World Health Organization/Institut Català d'Oncologia (WHO/ICO) 2010 report,¹⁰ and a secondary analysis of data published previously from the Tobago study performed by Ragin et al.¹⁴ The overall prevalence rate of cervical HR HPV infection, as well as the prevalence rate of HR HPV other than 16 or 18 infection, was significantly higher in Guadeloupe than in France and in developed regions ($p < 0.001$). Conversely, the crude prevalence of HPV 16 and/or 18 cervical infection was not significantly different between Guadeloupe and other countries. Interestingly, data from the Caribbean island of Tobago were of the same order of magnitude as those recorded in Guadeloupe.

Figure 1 presents the crude prevalence of overall HR HPV, HPV 16 and/or 18, and HR HPV other than 16 or 18 cervical infections by grade of cytology for each age group. Regardless of the cytology grade, the overall rate of HR HPV cervical infection decreased with age for women older than 29 years, except for the age group ≥65 years. The largest drop was observed in ASC-US for women aged

Table 1
Prevalence of HR HPV cervical infections by cytology grade

	Cytology grade									<i>p</i> -Value
	Normal (<i>n</i> = 447)			ASC-US (<i>n</i> = 106)			LSIL (<i>n</i> = 31)			
	<i>n</i>	%	95% CI	<i>n</i>	%	95% CI	<i>n</i>	%	95% CI	
Overall HR HPV	112	25.1	21.1–29.3	69	65.1	55.2–74.1	24	77.4	58.9–90.4	<0.001
HR HPV 16 and/or 18 irrespective of other HR HPV types	24	5.4	3.5–7.9	12	11.3	6.0–18.9	3	9.7	2.0–25.8	0.060
Other HR HPV excluding 16 and 18	88	19.7	16.1–23.7	57	53.8	43.8–63.5	21	67.7	48.6–83.3	<0.001

HR, high-risk; HPV, human papillomavirus; ASC-US, atypical squamous cell of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; CI, confidence interval.

Download English Version:

<https://daneshyari.com/en/article/3361929>

Download Persian Version:

<https://daneshyari.com/article/3361929>

[Daneshyari.com](https://daneshyari.com)